CS54: Sex, Drugs and Oral Cancer

Recent trends in oral cancer have heightened the importance of a proper oral cancer screening protocol for all medical and dental professionals. Oral Cancer has risen each of the past seven years, and the deforming disease is now affecting patients with no traditional risk factors. Due to a 225% increase in HPV related oropharyngeal cancers, oral cancer is occurring in younger populations, changing the perception of who to screen.

With the need for a new oral cancer screening protocol, adjunctive screening options will be covered in detail. This course will introduce recent and emerging technologies for early discovery of oral cancer, including fluorescence technology and quantitative cytology along with the importance of proper implementation. Clinical examples of these procedures will also be provided.

As cancer therapies continue to evolve, two main side effects from most cancer treatments are xerostomia and mucositis, two oral health concerns. Common side effects and treatment options will be covered for the everyday oncology patient.

ABOUT OUR PRESENTER

Robert J. Whitman is a graduate of Tulane University with a B.S. and M.S.E. in Biomedical Engineering, Robert brings a unique mindset to the medical device industry. Robert began his career at M.D. Anderson Cancer Center as a Clinical Engineer utilizing advanced technology for early detection of cervical cancer. With a passion for early cancer diagnostics, Robert then joined the Research and Development team at a private startup, developing cancer-screening products utilizing fluorescence technology licensed from M.D. Anderson Cancer Center.

Shortly thereafter, Robert co-founded Forward Science LLC, a medical device company established with the goal of advancing oral healthcare through early discovery (OralID), diagnostics (CytID, PathID, hpvID, phID), and treatment options (SalivaMAX). Robert is now the CEO of Forward Science and speaks nationally on the topic oral cancer and early discovery.

$37.50

BUY NOW